Cardiff Oncology is a clinical-stage biotechnology company on a mission to develop innovative therapeutic options for cancer patients. Their focus is on leveraging PLK1 inhibition to target a range of cancers and develop novel therapies. Their lead asset, onvansertib, is a PLK1 inhibitor that is being evaluated in combination with standard of care (SoC) therapeutics in clinical programs.

The goal is to provide new treatment options for indications with the greatest need. By targeting tumor vulnerabilities and overcoming treatment resistance, Cardiff Oncology aims to deliver superior clinical benefits to patients compared to the SoC. With a strong emphasis on research and development, they are actively working on a pipeline of promising therapies.

Cardiff Oncology's programs hold immense potential and are turning the tide on cancer, offering hope to countless individuals fighting the disease